Diabetes
Conditions
Keywords
Diabetes, Glucagon, Metabolic clearance rate of glucagon
Brief summary
The study aims to evaluate the elimination and degradation of glucagon in patients with type 2 diabetes compared to matched healthy subjects.
Detailed description
In the present project the investigators wish to identify whether the elimination and degradation of glucagon differ between healthy control subjects and patients with type 2 diabetes. Furthermore, the investigators wish to examine whether obesity is an independent factor for altered glucagon metabolism. Thus, by examining glucagon elimination in obese subjects with and without type 2 diabetes and in lean subjects with and without type 2 diabetes the investigators will be able to describe the metabolic clearance rate (MCR) of glucagon in a broad spectrum of individuals with different levels of insulin resistance and beta cell dysfunction.
Interventions
BIOLOGICALGlucagon
One hour glucagon-clamp followed by one hour of blood sampling
Sponsors
University of Copenhagen
European Foundation for the Study of Diabetes
University Hospital, Gentofte, Copenhagen
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
Patients with type 2 diabetes * Caucasians above 35 years of age with diet or/and metformin-treated type 2 diabetes of at least 3 month duration (diagnosed according to World Health Organization (WHO) criteria * BMI either below 27 or above 33 kg/m\^2 * Normal haemoglobin * Informed consent Subjects with NGT * Caucasians above 35 years of age * BMI either below 27 or above 33 kg/m\^2 * Normal HbA1c (according to WHO criteria) * Normal haemoglobin * Informed consent
Exclusion criteria
Patients with type 2 diabetes * Inflammatory bowel disease * Operation within the last 3 months * Severe kidney disease (eGFR \< 60 ml/min) * Severe liver disease (serum alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) \>2×normal values) * Pregnancy and/or breastfeeding * Age above 80 years * Any condition that the investigators feel would interfere with trial participation Subjects with NGT * Diabetes * Prediabetes (impaired FPG or HbA1c above 42 mmol/mol) * First-degree relatives with diabetes * Inflammatory bowel disease * Intestinal resection * Severe kidney disease (eGFR \< 60 ml/min) * Liver disease (ALA T and/or serum ASA T \>2×normal values) * Pregnancy and/or breastfeeding * Age above 80 years Any condition that the investigators feel would interfere with trial participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Metabolic clearance rate of glucagon | -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes |
Secondary
| Measure | Time frame |
|---|---|
| Gut and pancreatic hormones | -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes |
| Blood glucose | -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes |
| Basic metabolic rate | -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes |
| Half life of glucagon | -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes |
| The volume of distribution of glucagon | -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes |
| Satiety, hunger, appetite - measured with visual analogue scales (VAS) | -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes |
Countries
Denmark
Outcome results
None listed